PARP inhibitors
1 product
59 abstracts
Abstract
First-in-human phase I trial of the oral first-in-class ubiquitin specific peptidase 1 (USP1) inhibitor KSQ-4279 (KSQi), given as single agent (SA) and in combination with olaparib (OLA) or carboplatin (CARBO) in patients (pts) with advanced solid tumors, enriched for deleterious homologous recombination repair (HRR) mutations.Org: KSQ Therapeutics, Cambridge, MA, Roche Pharma Research and Early Development, Roche Innovation Center, Dana-Farber Cancer Institute, Hackensack University Medical Center,
Abstract
A first-in-human (FIH), phase 1/2, dose-escalation, dose-optimization, and dose-expansion study of PARP1-selective inhibitor IMP1734 in participants with advanced solid tumors.Org: AdventHealth Cancer Institute, START Mountain Region, Sarah Cannon Research Institute at HealthONE, Sarah Cannon Research Institute/Tennessee Oncology, START San Antonio,
Abstract
Clinical landscape of precision oncology for rare cancers among diverse Asian populations: Insights from the MASTER KEY registry.Org: Department of International Clinical Development, National Cancer Center Hospital, Tokyo, Japan, Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan, Department of Therapeutic Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, Division of Clinical Cancer Genomics, Hokkaido University Hospital, Hokkaido, Japan, Department of Oncology and Social Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan,
Abstract
Phase II study of a PARP inhibitor, talazoparib, in HER2- metastatic breast cancer (MBC) with a somatic BRCA1/2 mutation identified in a cell-free DNA or tumor tissue genotyping assay.Org: Massachusetts General Hospital Cancer Center, Harvard Medical School, The University of Texas MD Anderson Cancer Center, Emory University School of Medicine, Massachusetts General Hospital,
Abstract
Comprehensive molecular profiling of newly diagnosed advanced, high-grade ovarian cancer: Unveiling BRCA1/2 mutations and genomic instability scores to advocate for public insurance coverage of genetic testing—Insights from the Hellenic Society of Medical Oncology (HeSMO) national program.Org: Hellenic Society of Medical Oncology,
Abstract
(CDK) 4/6 inhibitors: An effective treatment for homologous recombination deficient (HRD) luminal breast cancers (BC)?Org: UNEB,
Abstract
The prevalence of RCTs in PARP and immune-checkpoint blockade combination trials: An appraisal of clinical evidence generation in oncology.Org: Beth Israel Deaconess Medical Center, Boston, MA, Cancer Research Institute, New York City, NY, New York, NY,
Abstract
Rationale and study design of the KOV-HIPEC-04: A phase III randomized controlled trial in primary stage III and IV ovarian cancer after interval cytoreductive surgery (FOCUS).Org: Biomedical Statistics Center, Samsung Medical Center, Department of Obstetrics and Gynecology, Yonsei University College of Medicine, Department of Obstetrics and Gynecology, Ajou University School of Medicine, Gynecologic Cancer Center, Kyungpook National University Medical Center, Department of Obstetrics and Gynecology, Korea University College of Medicine,
Abstract
Therapeutic potential of immune-cold solid tumors through homologous recombination deficiency.Org: OneCell Dx Inc., OneCell Dx, Indx Technology, OneCell Diagnostics,
Abstract
Pathways for provider initiated genetic testing to bridge the gap in germline genetic testing for metastatic breast cancer.Org: The University of Texas Health Science Center at Houston, McGovern Medical School, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX,
Abstract
A systematic review of racial disparity in pivotal poly (ADP-ribose) polymerase (PARP) inhibitor trials.Org: University of Tennessee Health Science Center, Memphis, TN, University of Tennessee Health Science Center, Piperton, TN,
Abstract
Association of homologous recombination repair mutation defined with a 15-gene panel with the prognosis of epithelial ovarian cancer: A Chinese multicenter retrospective study.Org: The Affiliated Zhongda Hospital, Southeast University, Zhejiang Cancer Hospital, Chinese Academy of Sciences, Department of Obstetrics and Gynecology, Core Facility Center, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Department of Obstetrics and Gynaecology, Zhongda Hospital, School of Medicine, Southeast University,
Abstract
Real world experience of molecular landscape of uveal melanomas: Implications for personalized medicine strategies.Org: Leaders in Oncology Care, HCA Healthcare UK,
Abstract
First-line treatment patterns among patients with metastatic pancreatic ductal adenocarcinoma in the real-world setting.Org: Ipsen Biopharmaceuticals,
Abstract
Luveltamab tazevibulin (STRO-002), an anti-folate receptor alpha (FolRα) antibody drug conjugate (ADC), safety and efficacy in a broad distribution of FolRα expression in patients with recurrent epithelial ovarian cancer (OC): Update of STRO-002-GM1 phase 1 dose expansion cohort.Org: Vall d’Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, The Ohio State University James Cancer Center, Sidney Kimmel Cancer Center at Thomas Jefferson University, University of Chicago,
Abstract
Effect of homologous recombination deficient (HRD) breast cancers on a distinct immune marker phenotype by comprehensive genomic and immune profiling (CGIP).Org: Labcorp Oncology, Duke University Medical Center, Duke Cancer Institute, Department of Pathology, Durham, NC, OmniSeq (Labcorp), Duke University Medical Center, Duke Cancer Institute, OmniSeq, Inc.,
Abstract
PSMA expression and response to 177Lu-PSMA-617 (LuPSMA) in men with vs. without DNA damage repair (DDR) mutations.Org: Fred Hutchinson Cancer Center/Division of Hematology and Oncology, University of Washington and Fred Hutchinson Cancer Research Centre,
Abstract
The somatic mutation profile of breast cancer in Uganda.Org: Fred Hutchinson Cancer Center/Division of Hematology and Oncology, Uganda Cancer Institute (Uganda), Department of Laboratory Medicine and Pathology, University of Washington, Hutchinson Centre Research Institute, Uganda Cancer Institute,
Abstract
Investigation of synthetic lethality gene pairs in the DNA damage response pathway in response to immunotherapy in pan-cancer.Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Beijing Shijitan Hospital, Capital Medical University, The Medical Department, Jiangsu Simcere Diagnostics Co., Ltd., 3D Medicine Inc.,
Abstract
Tandem duplicator phenotype: A novel targetable subgroup in pancreatic cancer?Org: Princess Margaret Cancer Centre, Ontario Institute for Cancer Research, Toronto, ON, Canada, Trinity St. James’s Cancer Institute, University of Toronto, University Health Network,
Abstract
Oregovomab and non-platinum chemotherapy in PARP inhibitor-resistant ovarian, fallopian tube, or primary peritoneal cancer patients not candidates for platinum retreatment: A multicenter, two-cohort, single-arm phase 2 trial (OPERA/KGOG 3065/APGOT-OV6).Org: Yonsei University College of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Korea University College of Medicine, Seoul National University Bundang Hospital,
Abstract
Homologous recombination deficiency (HRD) in non-small cell lung cancer: Genomic analysis using an RNA-based HRD algorithm.Org: Tempus Labs, Inc., University of Pennsylvania, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center,
Abstract
Clinical implications of molecular alterations in intraductal carcinoma of the prostate.Org: Fox Chase Cancer Center, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy, Caris Life Sciences, Irving, TX, Oncologia D`Or, A.C. Camargo Cancer Center,
Abstract
Exploring the prognostic and predictive impact of genomic loss of heterozygosity (LOH) in patients with metastatic colorectal cancer (mCRC).Org: Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana and Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy, Charité Universitätsmedizin Berlin, Berlin, Germany, Oncology Unit 1, Veneto Institute of Oncology IOV – IRCCS, Padua, Italy, Department of Medical Oncology, University Campus Biomedico, Roma, Italy, Division of Clinical Pharmacology and Oncology, Department of Health Sciences, School of Psychology, University of Florence, Florence, Italy, University of Pisa, Pisa, Italy, Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy and Oncology Unit 1 Veneto Institute of Oncology - IRCCS Padua, Padua, Italy, U.O.C. Oncologia Medica, Presidio Ospedaliero Livorno, Livorno, Italy, Hämatologisch Onkologische Praxis Eppendorf (HOPE) and Universitäres Cancer Center Hamburg, Universitätsklinikum Hamburg Eppendorf, Hamburg, Germany, Azienda Ospedaliero-Universitaria Pisana, Istituto Toscano Tumori, Pisa, Italy, Department of Oncology, Istituto Scientifico San Raffaele IRCSS, Milan, Italy, CdC Poliambulanza, Brescia, Italy, Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy and Oncology Unit 1 Veneto Institute of Oncology - IRCCS, Padua, Italy, IRCSS-CRO Aviano, Department of Clinical Oncology, Aviano, Italy, Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, Martin Luther University, Halle, Germany, Azienda Ospedaliera Universitaria Pisana, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa & Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy, University of Pisa, Pisa, Italy, University Campus Biomedico,
Abstract
Response to subsequent platinum-based chemotherapy post PARP inhibitor in recurrent epithelial ovarian cancer.Org: University of Ottawa, Ottawa, ON, Canada, OHRI, The Ottawa Hospital Research Institute,
Abstract
The spectrum of homologous recombination deficiency in cervical cancer: Is it also a cervical issue?Org: Weill Cornell Medicine - Qatar, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, Memorial Sloan Kettering Cancer Center,
Abstract
Utility of surgically documented minimal residual disease as a therapeutic target and early surrogate of frontline treatment outcomes in ovarian cancer.Org: University of Texas MD Anderson Cancer Center, University of Texas at MD Anderson Cancer Center,
Abstract
Proactive assessment of patient reported outcomes in patients with ovarian cancer.Org: 12 de Octubre University Hospital, Wollongong Hospital, Princess Margaret - University Health Network, Hospital Universitario 12 de Octubre, Medical Oncology Department, Presidio Ospedaliero Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy,
Abstract
A phase 1/2 study of combination olaparib and radium-223 in men with metastatic castration-resistant prostate cancer with bone metastases (COMRADE): A trial in progress.Org: Mount Auburn Hospital, Harvard Medical School, Cambridge, MA, Department of Data Sciences, Dana-Farber Cancer Institute,
Abstract
Skin adverse events of anti-cancer treatments: An examination of drug-AE associations.Org: La Roche-Posay International, Levallois-Perret, Institut Universitaire du Cancer Toulouse-Oncopole, Toulouse, Memorial Sloan Kettering Cancer Center,
Abstract
TEDOVA/GINECO-OV244b/ENGOT-ov58 trial: Neo-epitope based vaccine OSE2101 alone or in combination with pembrolizumab vs best supportive care (BSC) as maintenance in platinum-sensitive recurrent ovarian cancer with disease control after platinum.Org: Gustave-Roussy Cancer Campus, Institut Claudius Regaud, IUCT-Oncopole Toulouse, Institut Paoli Calmettes, Biostatistic Unit, IRCCS Humanitas Research Hospital, Rozzano (Milano), Italy,
Abstract
Healthcare utilization among individuals diagnosed with hereditary breast-ovarian cancer syndrome through a universal germline genetic testing program.Org: City of Hope Comprehensive Cancer Center, City of Hope National Medical Center, City of Hope National Comprehensive Cancer Center,
Abstract
Therapeutic applications of germline testing for cancer predisposition genes in Asia in the real world.Org: National University Cancer Institute, National University Hospital, Icon Cancer Centre, NUHS,
Abstract
An in-house testing for detection of homologous recombination repair deficiency (HRD) in patients with solid tumors.Org: Department of Gastrointestinal Surgery, Hengyang Central Hospital, Hengyang, China, Quanzhou First Hospital.Fujian, Quanzhou, China, Department of Anesthesiology,Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China, HaploX Biotechnology Co., Ltd., Shenzhen, China, HaploX Biotechnology, Shenzhen, China,
Abstract
Homologous recombination-related (HRR) gene mutation profiling and the association with TMB in Chinese patients with esophageal and gastric cancer.Org: Nanjing Simcere Medical Laboratory Science Co., Ltd., Jiangsu simcere diagnostics Co,.Ltd, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd.,
Abstract
Anticancer–drug-induced interstitial lung disease (DIILD): With great power comes great responsibility.Org: Syneos Health, Morrisville, NC, NC Medical Research, Gurugram, Indiana University – Purdue University Indianapolis,
Abstract
Rates of potentially actionable germline variants in homologous recombination repair genes in a large international cohort outside of the United States.Org: Invitae, Lee Kong Chian School of Medicine, Nanyang Technological University, Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán, Mexico City, Mexico,
Abstract
The landscape of ATM alteration in Chinese solid tumor patients.Org: Ya’an People’s Hospital, Yinfeng Gene Technology Co Ltd, Huaxi Kindstar Medical Diagnostics (Sichuan) Co Ltd, Clinical Oncology Research Alliance,
Abstract
Dual inhibition of PARP and ATR induces homologous recombination repair deficiency and leads to synthetic lethality in prostate cancer with CDK12 alteration.Org: Department of Urology, Nagoya University Graduate School of Medicine, Nagoya, Japan, Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan, Deparment of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan, Genome Dynamics Project, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan,
Abstract
Immunogenicity after COVID-19 vaccination in patients with solid tumor and hospital staff: A prospective single-center observational study.Org: Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan, National Cancer Center Hospital, Tokyo, Japan, Department of Stem Cell Transplantation, National Cancer Center, Chuo-Ku, Tokyo, Japan, sysmex, Kobe, Japan, Center for Breast Cancer, National Cancer Center, Chuo-Ku, Japan,
Abstract
A multi-center natural history study of precision-based genomics in prostate cancer (PC).Org: Dana-Farber Cancer Institute, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain, Memorial Sloan Kettering Cancer Center, University of California San Diego,
Abstract
Impact of postoperative residual disease in patients with primary epithelial ovarian cancer in the era of maintenance therapies with targeted agents: A systematic review and meta-analysis.Org: National Cancer Center Korea, Seoul National University College of Medicine, National Cancer Center Hospital East, Kashiwa, Japan, Pusan National University Yangsan Hospital, Seoul National University Hospital,
Abstract
Comprehensive ctDNA analysis to identify genome-instability and actionable mutation landscape in gynecologic cancers.Org: OneCell Dx, Indx Technology, Bhaktivedanta Hospital And Research Centre and School of Consciouness, MIT WPU, De Dy Patil Medical College & Research Centre,
Abstract
Outcomes of myeloid malignancies in patients previously treated with PARP inhibitors for solid malignancies: A single institution experience.Org: University of Texas MD Anderson Cancer Center, The University of Texas at MD Anderson Cancer Center, MD Anderson Cancer Center, Department of Leukemia,
Abstract
Correlation analysis to assess surrogate endpoints for overall survival (OS) in triple-negative breast cancer (TNBC).Org: The Larvol Group, LLC, Labcorp Drug Development Inc., Princeton, NJ, Addenbrooke’s Hospital, Cambridge University Hospitals NHS Trust,
Abstract
Homologous recombination-related (HRR) gene mutation profiling and the association with TMB in Chinese patients with urological cancer.Org: Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Jiangsu Institute of Cancer Research, Affiliated Cancer Hospital of Nanjing Medical University, Nanjing Simcere Medical Laboratory Science Co., Ltd., Jiangsu simcere diagnostics Co,.Ltd,
Abstract
The application of a multigene NGS assay in homologous recombination deficiency tracking.Org: Genekor, Genekor Medical S.A., Genekor Medical SA, Bioclinic Thessaloniki, National Kapodistrian University of Athens,
Abstract
Homologous recombination-related (HRR) gene mutation profiling and the association with TMB in Chinese patients with pancreatic cancer.Org: Nanjing Simcere Medical Laboratory Science Co., Ltd., Jiangsu simcere diagnostics Co,.Ltd, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd.,
Abstract
Identification of clinically actionable biomarkers in an Indian cancer cohort using comprehensive genomic profiling (CGP): An institutional experience.Org: Triesta Sciences, HCG Cancer Center Mumbai, Strand Life Sciences,
Abstract
Clinical features of long-term survivors with advanced high-grade serous ovarian cancer.Org: Medical Oncology Group, Catalan Institute of Oncology and Girona Biomedical Research Institute, Medical School University of Girona, Medical Oncology Department, Presidio Ospedaliero Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy, Catalan Institute of Oncology-Hospitalet,
Abstract
Phenotypic differences related to homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) treated in routine care settings in the United States (US).Org: Merck & Co., Inc., Merck and Co., Inc, Integra Connect PrecisionQ,
Abstract
Increasing targeted therapy options for mCRPC patients using multigene NGS panel.Org: Genekor Medical SA, Genekor Medical S.A., Naval & Veterans Hospital of Athens/Hellenic Navy, Psychiko Medical Center, Tansan Onkoloji,
Abstract
Association of tumor homologous recombination deficiency (HRD) score with immune checkpoint inhibitor benefit in metastatic clear cell renal cell carcinoma.Org: Levine Cancer Institute, Atrium Health Carolinas Medical Center, Department of Cancer Biostatistics,
Abstract
The combination of APR-246 and carboplatin in olaparib-resistant high grade serous ovarian cancer (HGSOC) and triple negative breast cancer (TNBC) cell lines.Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Hospital Clínico Universitario de Valencia, Instituto de Investigación Sanitaria (INCLIVA), Translational Oncology and Pathology Group, La Paz University Hospital-IdiPAZ,
Abstract
Homologous recombination deficiency (HRD) status and response to platinum-based chemotherapy and PARP inhibitors in Chinese patients with ovarian cancer.Org: Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China,
Abstract
How to close the care gap: Factors hindering the use of BRCA mutation profiling of patients with breast cancer and ovarian cancer in a real world setting.Org: MVR Cancer Centre & Research Institute,
Abstract
Efficacy of PARP inhibitors in patients with metastatic castration resistant prostate carcinoma: A meta-analysis of phase III randomized controlled trials.Org: Community Hospital of San Bernardino, Abbott Northwestern Hospital, SSM St Mary's hospital, University of California Riverside, SSM St Louis University hospital,
Abstract
Genetic testing in patients with pancreatic cancer to reveal pathogenic variants in cancer susceptibility genes.Org: Genekor, Genekor Medical SA, Memorial and Medstar, Kent Hospital, Fundeni Clinical Institut,
Abstract
Resistance mechanism and microenvironment changes after PARPi treatment: Paired analysis of ovarian cancer samples pre and post treatment.Org: Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, Chengdu, China, Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, Chengdu, China, Department of Pathology, West China Second University Hospital, Sichuan University, 610041, Sichuan Province, Chengdu, China, Amoy Diagnostics Co., Ltd., Xiamen, China,
Product
PARP inhibitors